Helus shares slide on psychedelic readout in depression
Helus Pharma has revealed data from a phase 3 trial of HLP003 that showed evidence of efficacy in major depressive disorder (MDD), but prompted a sharp fall in its share price on what appeared to be investor jitters about its safety.
In the APPROACH study, HLP003 (deuterated psilocin) or a placebo – taken orally at two separate, supervised dosing sessions spaced three weeks apart – was added to 222 patients' current antidepressant treatment for MDD. All the subjects were considered to have an inadequate response to their therapy at baseline.
The efficacy result looks strong, with the psychedelic achieving "statistically significant and clinically meaningful" 7.6-point improvement in depressive symptoms, measured using the Montgomery-Åsberg Depression Rating Scale (MADRS) at the six-week timepoint, with separation from placebo apparent from day two.
That was accompanied by a 7-point, placebo-adjusted MADRS reduction at week 12, a key secondary endpoint. Ahead of the readout, analysts had suggested an MADRS improvement of 5 or 6 points over placebo would be a baseline efficacy threshold, and that has been comfortably exceeded, encouraging Helus to say it is on course for regulatory approval and a potential launch of the therapy.
Moreover, clinical remission – a 10-point or less MADRS score – was seen in 39.3% of HLP003-treated patients at day two, versus 15.5% of the placebo group, and at day 84 the rates were 40.2% and 15.5%, respectively.
So why did Helus share price – trading down around 11% at the time of writing – take a tumble? The concern seems to be three treatment-related serious adverse events in the HLP003-treated arm of the study, including one attempted suicide in a subject who did not respond to the psychedelic, a derivative of the active ingredient in magic mushrooms.
The attempt occurred 55 days after the patient received a second dose. They were admitted to hospital two days after an overdose of their background antidepressant medication – which has a boxed warning for suicidality – and subsequently discharged.
Helus' chief medical officer Amir Inamdar said on a conference call that "While suicidality is a feature of depression, based on a comprehensive assessment of the APPROACH data…we did not observe a signal of suicidality" with the drug treatment.
Helus' chief executive Michael Halstead said on the call that the study is a "defining moment" for Helus and suggests that HLP003 could set "a new benchmark in adjunctive treatment of MDD."
At the moment, this treatment is generally provided using atypical antipsychotics, which offer a modest benefit and have well-established tolerability issues, including weight gain, cardiometabolic dysfunction, and movement disorders.
The company – which was formerly known as Cybin – hopes to file for approval of HLP003 in 2028, after reporting results from a second pivotal trial (EMBRACE) next year.
